Amneal Pharmaceuticals has announced the launch of its pegfilgrastim biosimilar, Fylnetra (pegfilgrastim-pbbk), for the treatment and prevention of febrile neutropenia, making it the sixth biosimilar referencing Neulasta to enter the US market.
Amneal Pharmaceuticals has announced the launch of its pegfilgrastim biosimilar, Fylnetra (pegfilgrastim-pbbk), for the treatment and prevention of febrile neutropenia, making it the sixth biosimilar referencing Neulasta to enter the US market.
The biosimilar is being offered in a prefilled single-dose syringe and was developed in collaboration with Kashiv Biosciences. It was approved in May 2022. The news comes after the launch of Eli Lilly and Company’s interchangeable insulin glargine biosimilar Rezvoglar (insulin glargine-aglr) in April 2023.
Pegfilgrastim is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. Febrile neutropenia is a common complication associated with chemotherapy, where patients have a low number of neutrophils to fight infections.
“Fylnetra marks our third US biosimilar launch since late last year. We are excited to be contributing to this next wave of affordable medicines, and we are well positioned to drive access across patients, providers, and payors. Although it’s only the early innings for the growing biosimilars market, we are focused on becoming a key player over the long term. These first 3 launches are just the start for Amneal in biosimilars,” said Harsher Singh, senior vice president of Amneal’s Biosciences division.
In addition to Fylnetra, the FDA has approved Nyvepria (pegfilgrastim-apgf; June 2020), Ziextenzo (pegfilgrastim-bmez; November 2019), Udenyca (pegfilgrastim-cbqv; November 2018), Stimufend (pegfilgrastim-fpgk; September 2022), and Fulphila (pegfilgrastim-jmdb; June 2018). The launch of Fylnetra also comes after Stimufend launched in February 2023 and the FDA approved an autoinjector version of Udenyca in March 2023.
“We are pleased to launch the Fylnetra biosimilar. This launch builds on our successful partnership with Amneal and the good uptake we are seeing of the Releuko biosimilar, which was launched in the fourth quarter of 2022. Kashiv is one of a few companies based in the United States to manufacture and launch multiple biosimilars. Kashiv aims to continue bringing high-quality biosimilars to the global markets over the coming years,” said Chandramauli Rawal, MD, chief operating officer at Kashiv.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.